Axsome Therapeutics (AXSM)
(Delayed Data from NSDQ)
$73.90 USD
-0.86 (-1.15%)
Updated Jun 7, 2024 04:00 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Brokerage Reports
Axsome Therapeutics, Inc. [AXSM]
Reports for Purchase
Showing records 161 - 177 ( 177 total )
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Multiple Positive Pipeline Developments; Narcolepsy Data Near-Term; Reiterate Buy; Raising Target to $30
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Multiple Positive Pipeline Developments; Narcolepsy Data Near-Term; Reiterate Buy; Raising Target to $30
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Breakthrough Therapy Designation Accorded to AXS-05; Treatment-Resistant Depression Data Near-Term; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
AXS-05 Hits Endpoints in Smoking Cessation Study; Two Out of Three Thus Far; Reiterate Buy and Raising Target to $23
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Positive AVP-786 Agitation Data Bode Well for AXS-05; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2018 Financial Results Reported; Lengthy Cash Runway; A Cornucopia of Catalysts; Raising Target to $18
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MOMENTUM Phase 3 Migraine Trial Kicks Off; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Special Protocol Assessment Finalized for Migraine Pivotal Trial; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
AXS-12 Enters Phase 2 Narcolepsy Study; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Fixed-Dose Combinations Common in Pharma; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Positive Phase 2 Top-Line Data in Major Depressive Disorder; Raising Target to $15
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Entering a Catalyst-Rich Period; Solid Financial Position; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
AXS-05 Alzheimer''s Agitation R-D Day Showcases Opportunity; AXS-12 Unveiled in Narcolepsy; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Potential Value From Neridronic Acid; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q 2018 Financial Results Reported; Plethora of Clinical Catalysts Approaching; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Axsome Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Threading a Path Through the Minefield; Initiating at Buy and $10 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R